You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
12.04.17
Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
11.28.17
Ironwood Pharmaceuticals Strengthens Executive Leadership Team
11.02.17
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update
11.01.17
Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference
10.30.17
Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting
10.19.17
Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call
10.16.17
Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017
09.06.17
Ironwood Pharmaceuticals Announces Leadership Change
08.31.17
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
08.21.17
Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
08.03.17
Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
07.20.17
Ironwood Pharmaceuticals to Host Second Quarter 2017 Investor Update Call
07.20.17
Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease
06.08.17
Ironwood Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
06.01.17
Ironwood Pharmaceuticals to Present at the Jefferies Healthcare Conference
05.10.17
Ironwood Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
05.09.17
Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide’s Effect on Pain at Digestive Disease Week® 2017
05.08.17
Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update
05.01.17
Ironwood Pharmaceuticals to Present New Data for Linaclotide, Linaclotide Delayed Release and IW-1701 at Digestive Disease Week® 2017
04.24.17
Ironwood Pharmaceuticals to Host First Quarter 2017 Investor Update Call
04.13.17
Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)
04.06.17
Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer
03.10.17
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference
03.09.17
Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines to Patients and Building a Top-Performing Commercial Biotech at R&D Day 2017
02.28.17
Ironwood Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
02.23.17
Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017
02.21.17
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
02.07.17
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call
01.29.17
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
01.26.17
U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation
01.08.17
Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech
01.04.17
Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
01.04.17
Ironwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
01.03.17
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
MEDIA & INVESTOR RELATIONS CONTACT
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com


Latest Tweets